Biomarin recently presented compelling new data demonstrating that VOXZOGO (vosoritide) significantly aids skull growth in patients with achondroplasia, a common form of dwarfism characterized by abnormal bone development. The findings highlight VOXZOGO’s potential in addressing cranial issues associated with achondroplasia, improving patient outcomes and quality of life. This breakthrough treatment works by targeting the genetic pathways that cause impaired bone growth, making it a promising option for managing the condition. The data also reinforce VOXZOGO’s broader benefits in promoting overall growth in children facing challenges linked to achondroplasia. As research advances, this development marks an important step toward more effective therapies addressing both height and cranial abnormalities in affected individuals. Biomarin’s continued commitment to innovation underscores the potential impact of VOXZOGO in transforming care paradigms for rare genetic disorders like achondroplasia.
PluangNew data shows data centers driving rapid growth in U.S. battery storage industry
October 10, 2026
New data reveals that data centers are playing a pivotal role in fueling a significant boom in the U.S. battery storage market. As demand for